Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment

Priyanka Nair-Gupta, Stephen I. Rudnick, Leopoldo Luistro, Melissa Smith, Ronan McDaid, Yingzhe Li, Kodandaram Pillarisetti, Jocelin Joseph, Bradley Heidrich, Kathryn Packman, Ricardo Attar, François Gaudet

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Redirecting T cells to specifically kill malignant cells has been validated as an effective anti-cancer strategy in the clinic with the approval of blinatumomab for acute lymphoblastic leukemia. However, the immunosuppressive nature of the tumor microenvironment potentially poses a significant hurdle to T cell therapies. In hematological malignancies, the bone marrow (BM) niche is protective to leukemic stem cells and has minimized the efficacy of several anti-cancer drugs. In this study, we investigated the impact of the BM microenvironment on T cell redirection. Using bispecific antibodies targeting specific tumor antigens (CD123 and BCMA) and CD3, we observed that co-culture of acute myeloid leukemia or multiple myeloma cells with BM stromal cells protected tumor cells from bispecific antibody-T cell-mediated lysis in vitro and in vivo. Impaired CD3 redirection cytotoxicity was correlated with reduced T cell effector responses and cell–cell contact with stromal cells was implicated in reducing T cell activation and conferring protection of cancer cells. Finally, blocking the VLA4 adhesion pathway in combination with CD3 redirection reduced the stromal-mediated inhibition of cytotoxicity and T cell activation. Our results lend support to inhibiting VLA4 interactions along with administering CD3 redirection therapeutics as a novel combinatorial regimen for robust anti-cancer responses.

Original languageEnglish
Article number65
JournalBlood Cancer Journal
Volume10
Issue number6
DOIs
StatePublished - 1 Jun 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment'. Together they form a unique fingerprint.

Cite this